Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

P4623Impact of left ventricular ejection fraction in ischemic and bleeding risk after an acute coronary syndrome

View through CrossRef
Abstract Introduction Even though left ventricular ejection fraction (LVEF) is a well-documented strong predictor of mortality after an acute coronary syndrome (ACS), its differential impact on the ischemic and bleeding risk of hemorrhage and ischemia is not well established. The aim of this study was to assess the impact of LVEF, measured by echocardiography, on the risk of acute myocardial infarction (AMI) and major bleeding (MB) after hospital discharge for ACS, during treatment with dual antiplatelet therapy (DAPT). Methods The data analyzed in this study were obtained from the fusion of 3 clinical registries of ACS patients: BleeMACS (2004–2013), CardioCHUVI/ARRITXACA (2010–2016) and RENAMI (2013–2016). All 3 registries include consecutive patients discharged after an ACS with DAPT and undergoing PCI. From the initial merged data set, that contained 26,076 patients, we have excluded those without data about LVEF. So the final cohort was composed by 20,518 patients. The impact of LVEF in the ischemic and bleeding risk was assessed by a multivariable competitive risk analysis, using a Fine and Gray regression model, with death being the competitive event. All those variables with statistical (p<0.05) or clinical significance for the association with AMI and MB were included in the analysis. Follow-up time was censored by DAPT suspension/withdrawal. Results During a mean follow-up of 12.2±5.2 months, 789 patients died (3.8%), 431 had an AMI (2.1%) and 537 had a MB (2.6%). The mean of LVEF was 53.2% ± 10.7%. Only 15.5% of patients had LVEF <40% (n=3,179). As the LVEF decreased, the risk of AMI increased, whereas the behavior of the risk of MB was more heterogeneous (Figure). After a multivariable adjustment, LVEF (as continuous variable) was significantly associated with AMI (sHR 0.98, 95% CI 0.98–0.99; p=0.010), but not with MB (sHR 1.00, 95% CI 0.99–1.01; p=0.270). After stratifying by LVEF groups (≥ vs <40%), we found an association between LVEF and AMI (sHR 1.40, 95% CI 1.10–1.76; p=0.005), but not between LVEF and bleeding (HR 0.85, 95% CI 0.67–1.08; p=0.185). Conclusions After an ACS, as the LVEF decreases, there is an increase in ischemic risk, but not in bleeding risk. A LVEF <40% was independently associated with higher risk of AMI, but not with higher risk of MB.
Title: P4623Impact of left ventricular ejection fraction in ischemic and bleeding risk after an acute coronary syndrome
Description:
Abstract Introduction Even though left ventricular ejection fraction (LVEF) is a well-documented strong predictor of mortality after an acute coronary syndrome (ACS), its differential impact on the ischemic and bleeding risk of hemorrhage and ischemia is not well established.
The aim of this study was to assess the impact of LVEF, measured by echocardiography, on the risk of acute myocardial infarction (AMI) and major bleeding (MB) after hospital discharge for ACS, during treatment with dual antiplatelet therapy (DAPT).
Methods The data analyzed in this study were obtained from the fusion of 3 clinical registries of ACS patients: BleeMACS (2004–2013), CardioCHUVI/ARRITXACA (2010–2016) and RENAMI (2013–2016).
All 3 registries include consecutive patients discharged after an ACS with DAPT and undergoing PCI.
From the initial merged data set, that contained 26,076 patients, we have excluded those without data about LVEF.
So the final cohort was composed by 20,518 patients.
The impact of LVEF in the ischemic and bleeding risk was assessed by a multivariable competitive risk analysis, using a Fine and Gray regression model, with death being the competitive event.
All those variables with statistical (p<0.
05) or clinical significance for the association with AMI and MB were included in the analysis.
Follow-up time was censored by DAPT suspension/withdrawal.
Results During a mean follow-up of 12.
2±5.
2 months, 789 patients died (3.
8%), 431 had an AMI (2.
1%) and 537 had a MB (2.
6%).
The mean of LVEF was 53.
2% ± 10.
7%.
Only 15.
5% of patients had LVEF <40% (n=3,179).
As the LVEF decreased, the risk of AMI increased, whereas the behavior of the risk of MB was more heterogeneous (Figure).
After a multivariable adjustment, LVEF (as continuous variable) was significantly associated with AMI (sHR 0.
98, 95% CI 0.
98–0.
99; p=0.
010), but not with MB (sHR 1.
00, 95% CI 0.
99–1.
01; p=0.
270).
After stratifying by LVEF groups (≥ vs <40%), we found an association between LVEF and AMI (sHR 1.
40, 95% CI 1.
10–1.
76; p=0.
005), but not between LVEF and bleeding (HR 0.
85, 95% CI 0.
67–1.
08; p=0.
185).
Conclusions After an ACS, as the LVEF decreases, there is an increase in ischemic risk, but not in bleeding risk.
A LVEF <40% was independently associated with higher risk of AMI, but not with higher risk of MB.

Related Results

Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct Introduction Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION CARDIOVERSION AND F
RELATIONSHIP BETWEEN ATRIAL FIBRILLATION CARDIOVERSION AND F
Objectives To investigate the relationship between atrial fibrillation cardioversion and f wave in electrocardiogram, providing an ordinary and noninvasive method...
CMR EVALUATION OF CARDIAC FUNCTION IN PATIENTS WITH METABOLIC SYNDROME IMPACT ON THE STUDY OF HYPERTENSION
CMR EVALUATION OF CARDIAC FUNCTION IN PATIENTS WITH METABOLIC SYNDROME IMPACT ON THE STUDY OF HYPERTENSION
Objectives MRI in the evaluation of the metabolic syndrome (metabolic syndrome, MS) on left ventricular function in hypertensive patients in clinical application....
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Introduction Despite prophylactic platelet transfusions, World Health Organization (WHO) grade ≥ 2 bleeding occurs in 50 to 70% of patients with hematologic malignan...

Back to Top